Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Gut microbes may reveal who is at risk of type 2 diabetes years before diagnosis

28

May 2026

Gut microbes may reveal who is at risk of type 2 diabetes years before diagnosis

A large Swedish prospective cohort study found that specific gut microbial species and metabolic pathways measured years before diagnosis were associated with future type 2 diabetes risk. The findings suggest that gut microbiome composition and functional potential may help explain T2D development, but replication is needed before clinical use.

Ocrelizumab slows disability progression in advanced progressive multiple sclerosis

28

May 2026

Ocrelizumab slows disability progression in advanced progressive multiple sclerosis

A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab – a medication already prescribed to some patients with MS – significantly slows disability progression in people with primary progressive multiple sclerosis (PPMS), including older patients and those with more advanced disease who are wheelchair users.

Gut changes linger years after polyp removal and may signal colorectal cancer risk

28

May 2026

Gut changes linger years after polyp removal and may signal colorectal cancer risk

Researchers found that women who had undergone colorectal adenoma resection still showed gut microbiome and fecal metabolome alterations an average of about 12 years later. These persistent changes partly resembled colorectal cancer-associated patterns, suggesting that the host-microbiome axis may remain altered along the adenoma-cancer continuum.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.